NCT04647955View on ClinicalTrials.gov

Functional Dyspepsia: Validation of a Questionnaire for Symptom Assessment in FD PDS Subgroup

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 22, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Functional DyspepsiaPostprandial Fullness Syndrome
Interventions
DRUG

Itopride

Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.

DRUG

Placebo

Patients were treated for 8 weeks.

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT04647955 - Functional Dyspepsia: Validation of a Questionnaire for Symptom Assessment in FD PDS Subgroup | Biotech Hunter | Biotech Hunter